Exelixis Makes The Case For Early Filing Of Cabozantinib In Frontline Kidney Cancer
Company recruited clinical experts to explain why Phase II CABOSUN should be enough for approval and why a Phase III study is now impractical.
You may also be interested in...
Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.
One of a trio of new drugs shaking up the kidney cancer market, Cabometyx (cabozantinib) does better than expected in its first nine weeks on the US market, and additional indications are on the near horizon.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.